インフルエンザワクチンの世界市場2020-2063

◆英語タイトル:GLOBAL INFLUENZA VACCINE MARKET FORECAST 2020-2028
◆商品コード:INK20MY052
◆発行会社(リサーチ会社):Inkwood Research
◆発行日:2020年4月
◆ページ数:172
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算¥472,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はInkwood Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Inkwood Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートではインフルエンザワクチンの世界市場について調査・分析し、調査範囲・手法、エグゼクティブサマリー、市場動向、主要分析、種類別(四価ワクチン、三価ワクチン)分析、技術別(卵由来、細胞由来)分析、年齢層別(小児、成人)分析、投与経路別(注射、経鼻スプレー)分析、地域別分析、企業情報などの情報をお届けいたします。
・調査範囲・手法
・エグゼクティブサマリー
・市場動向
・主要分析
・インフルエンザワクチン世界市場:種類別(四価ワクチン、三価ワクチン)
・インフルエンザワクチン世界市場:技術別(卵由来、細胞由来)
・インフルエンザワクチン世界市場:年齢層別(小児、成人)
・インフルエンザワクチン世界市場:投与経路別(注射、経鼻スプレー)
・地域別分析
・企業情報
【レポートの概要】

KEY FINDINGS
The global influenza vaccine market is estimated to record a CAGR of 6.43% over the forecast period of 2020-2028. A surge in the cases of influenza is a significant factor fueling the market growth. The other driving factors for the market are the government immunization programs to eradicate ailments from society, along with technological advancements.

MARKET INSIGHTS
Influenza is an acute respiratory illness caused by the influenza virus that affects the respiratory tract. Influenza viruses change continuously. Hence the vaccines have to be changed annually to match with the circulating influenza strains globally. The focus of various immunization programs is on increasing awareness among people towards vaccinations. For example, NAIIS AND CDC across the U.S. have undertaken some of the successful influenza vaccination initiatives. The recommendations made by the CDC are highly reliable and enhance the utilization of vaccines.
The high cost of vaccine development is one of the challenges faced by the market. The development of vaccines comprises of various phases, and the overall time period required from the development to the launch of the vaccine, may take 15-20 years. The overall development requires high monetary investments, which is estimated to be $200 million and $500 million per vaccine. The intensity of competition is high in the market as the market is dominated by a few established players. The quadrivalent influenza vaccine captured the highest market share in type segment in 2019, and is also estimated to be the fastest-growing influenza vaccine type.

REGIONAL INSIGHTS
The global influenza vaccine market is analyzed on the basis of the markets situated in North America, Europe, Asia Pacific, and the Rest of the world. The North American region dominates in terms of revenue, which is attributed to the rising incidences of influenza.

COMPETITIVE INSIGHTS
The market is dominated by well-established players such as Pfizer, Inc, Merck, Sanofi, Novartis AG, F. Hoffmann-La Roch Ltd, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

【レポートの目次】

1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES `
2.2. MARKET OVERVIEW
3. MARKET DYNAMICS
3.1. PARENT MARKET ANALYSIS: VACCINE MARKET
3.2. MARKET DEFINITION
3.3. KEY DRIVERS
3.3.1. GOVERNMENT IMMUNIZATION PROGRAMS TO ERADICATE AILMENTS FROM THE SOCIETY
3.3.2. RISE IN THE CASES OF INFLUENZA
3.3.3. TECHNOLOGY ADVANCEMENT
3.4. KEY RESTRAINTS
3.4.1. HIGH COST OF DEVELOPMENT
3.4.2. LENGTHY PROCESS OF DEVELOPMENT
4. KEY ANALYTICS
4.1. KEY INVESTMENT INSIGHTS
4.2. PORTER’S FIVE FORCE ANALYSIS
4.2.1. BUYER POWER
4.2.2. SUPPLIER POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. OPPORTUNITY MATRIX
4.4. VENDOR LANDSCAPE
5. MARKET BY TYPE
5.1. QUADRIVALENT VACCINE
5.2. TRIVALENT VACCINE
6. MARKET BY TECHNOLOGY
6.1. EGG-BASED TECHNOLOGY
6.2. CELL-BASED TECHNOLOGY
7. MARKET BY AGE GROUP
7.1. PEDIATRIC AGE GROUP
7.2. ADULT AGE GROUP
8. MARKET BY DELIVERY MODE
8.1. INJECTION
8.2. NASAL SPRAY
9. GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1. UNITED STATES
9.1.2. CANADA
9.2. EUROPE
9.2.1. UNITED KINGDOM
9.2.2. GERMANY
9.2.3. FRANCE
9.2.4. ITALY
9.2.5. RUSSIA
9.2.6. BELGIUM
9.2.7. POLAND
9.2.8. REST OF EUROPE
9.3. ASIA PACIFIC
9.3.1. CHINA
9.3.2. JAPAN
9.3.3. INDIA
9.3.4. SOUTH KOREA
9.3.5. AUSTRALIA & NEW ZEALAND
9.3.6. THAILAND
9.3.7. INDONESIA
9.3.8. VIETNAM
9.3.9. REST OF ASIA PACIFIC
9.4. REST OF WORLD
9.4.1. LATIN AMERICA
9.4.2. MIDDLE EAST & AFRICA
10. COMPANY PROFILES
10.1. MERCK
10.2. NOVARTIS AG
10.3. PFIZER, INC
10.4. SANOFI
10.5. BIODIEM
10.6. EMERGENT BIOSOLUTIONS
10.7. F. HOFFMANN-LA ROCHE LTD
10.8. GLAXOSMITHKLINE
10.9. ABBOTT
10.10. CSL LTD



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザワクチンの世界市場2020-2063]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆